GelMEDIX

GelMEDIX, Catalent Partner to Advance iPSC-Derived Cell Therapies

Leslie BHA2026-03-27T14:07:29-04:00GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent Inc., a global contract development and manufacturing organization (CDMO), have partnered to utilize Catalent’s GMP-induced pluripotent stem cells (iPSC) and cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases. Read More>>

GelMEDIX Completes $13 Million Seed Financing and Announces First Partnership

Leslie BHA2026-02-17T14:01:03-05:00— Proceeds to support advancement of lead cell therapy program for Geographic Atrophy and next-generation hydrogel regenerative therapy platform — — Partnership with global pharmaceutical company will leverage GelMEDIX regenerative medicine technology to develop stem cell-derived cell therapies — CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- GelMEDIX, Inc., a biotechnology company developing regenerative therapies to restore vision, announced today the completion of a $13 million seed financing led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor...